Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL384786 | 0.91 | RAB9A (0.35) | ALDH1A1CYP1A2CYP2C9CYP2C19RECQL | |
| SCHEMBL4022801 | 0.88 | — | — | |
| SCHEMBL386444 | 0.79 | CYP2C19 (0.36) | ALDH1A1CYP1A2CYP2C19RECQLRAB9A | |
| SCHEMBL387516 | 0.78 | TAAR1 (0.32) | ALDH1A1RECQLSMN1; SMN2MAPT | |
| SCHEMBL4014366 | 0.78 | ALDH1A1 (0.43) | ALDH1A1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL1453846 | 0.76 | NPC1 (0.34) | ALDH1A1CYP1A2CYP2C9CYP2C19RECQL | |
| SCHEMBL7621704 | 0.74 | GRM2 (0.37) | ALDH1A1RECQL | |
| SCHEMBL386711 | 0.72 | — | — | |
| SCHEMBL7614876 | 0.71 | ALDH1A1 (0.46) | ALDH1A1RECQLRAB9ASMN1; SMN2MAPT | |
| Hydrochloric Acid SCHEMBL7622475 | 0.70 | S1PR1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090326038-A1 | Method for treating a immunology-related disease | SANKYO COMPANY, LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
| US-7638551-B2 | Amino alcohol compounds or phosphonic acid derivatives thereof | SANKYO COMPANY, LIMITED (JP) | 2009-12-29 | — | — | US | disclosed |
| EP-1471054-B1 | AMINO ALCOHOL DERIVATIVE OR PHOSPHONIC ACID DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THESE | DAIICHI SANKYO CO LTD (JP) | 2009-07-01 | — | — | EP | disclosed |
| US-20070142335-A1 | Amino alcohol compounds or phosphonic acid derivatives thereof | SANKYO COMPANY, LIMITED (JP) | 2007-06-21 | — | — | US | disclosed |
| US-20070105933-A1 | Amino alcohol compounds | SANKYO COMPANY, LIMITED (JP) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326038-A1 | Method for treating a immunology-related disease | C3AR1, HRH3, HRH2 | ALDH1A1 2821/4885CYP1A2 2003/4885CYP2C9 2225/4885 |
| US-20070105933-A1 | Amino alcohol compounds | ADH1C, C9, SSB | ALDH1A1 582/4885CYP1A2 259/4885CYP2C9 1032/4885 |
| US-20070142335-A1 | Amino alcohol compounds or phosphonic acid derivatives thereof | HRH3, C3AR1, HRH4 | ALDH1A1 1443/4885CYP1A2 2160/4885CYP2C9 2218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.